{"id":47,"date":"2021-03-21T17:24:48","date_gmt":"2021-03-21T16:24:48","guid":{"rendered":"http:\/\/crmw.fr\/?page_id=47"},"modified":"2026-08-13T12:57:27","modified_gmt":"2026-08-13T10:57:27","slug":"etat-de-la-recherche","status":"publish","type":"page","link":"https:\/\/crmw.fr\/?page_id=47","title":{"rendered":"Recherches en cours"},"content":{"rendered":"\n
\n
\n
\n
    \n
  1. Corr\u00e9lation g\u00e9notype-ph\u00e9notype dans la maladie de Willebrand de type 2N<\/li>\n<\/ol>\n<\/div>\n\n\n\n

    Description<\/span><\/strong><\/p>\n\n\n\n

    Corr\u00e9lation g\u00e9notype-ph\u00e9notype dans la maladie de Willebrand de type 2N<\/p>\n\n\n\n

    Avancement<\/span><\/strong><\/p>\n\n\n\n

    Publi\u00e9e <\/p>\n\n\n\n

    But<\/span><\/strong><\/p>\n\n\n\n

    D\u00e9crire l\u2019impact du g\u00e9notype sur le ph\u00e9notype biologique et clinique chez les patients atteints de Maladie de Willebrand 2N <\/p>\n\n\n\n

    Responsable de traitement : CRMW <\/p>\n\n\n\n

    Responsable scientifique : Dr M\u00e9lanie DANIEL <\/p>\n\n\n\n

    Autorisations r\u00e9glementaires -Note d’information<\/span><\/strong><\/p>\n\n\n\n

    Ce projet a \u00e9t\u00e9 int\u00e9gr\u00e9 par le DPO dans le registre des traitements du CHU de Lille sous le num\u00e9ro DEC23-107.<\/p>\n\n\n\n

    \n
    Note d’information projet 2N<\/a><\/div>\n<\/div>\n\n\n\n

    Cat\u00e9gories de personnes\/donn\u00e9es concern\u00e9es<\/strong> : <\/p>\n\n\n\n

                           Patients atteints de Maladie de Willebrand 2N<\/p>\n\n\n\n

                           Donn\u00e9es cliniques et biologiques<\/p>\n\n\n\n

                           Prise de traitement sp\u00e9cifique \u00e0 la Maladie de Willebrand<\/p>\n<\/div>\n<\/div>\n\n\n\n

    Vous pouvez exercer \u00e0 tout moment vos droits individuels d’acc\u00e8s \u00e0 vos donn\u00e9es ou \u00e0 celles de votre enfant, de rectification de celles-ci, de limitation ou d’opposition \u00e0 leur utilisation ou \u00e0 leur transmission (portabilit\u00e9), et d’effacement en vous adressant au D\u00e9l\u00e9gu\u00e9 \u00e0 la Protection des Donn\u00e9es (DPO) par courriel : dpo@chru-lille.fr<\/a><\/p>\n\n\n\n

    Publication<\/span><\/strong><\/p>\n\n\n\n

    \n
    Acc\u00e9der \u00e0 la publication<\/a><\/div>\n<\/div>\n\n\n\n

    <\/p>\n","protected":false},"excerpt":{"rendered":"

    Description Corr\u00e9lation g\u00e9notype-ph\u00e9notype dans la maladie de Willebrand de type 2N Avancement Publi\u00e9e But D\u00e9crire l\u2019impact du g\u00e9notype sur le<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":89,"menu_order":1,"comment_status":"closed","ping_status":"closed","template":"","meta":{"colormag_page_container_layout":"default_layout","colormag_page_sidebar_layout":"default_layout","footnotes":""},"class_list":["post-47","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/crmw.fr\/index.php?rest_route=\/wp\/v2\/pages\/47","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/crmw.fr\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/crmw.fr\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/crmw.fr\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/crmw.fr\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=47"}],"version-history":[{"count":47,"href":"https:\/\/crmw.fr\/index.php?rest_route=\/wp\/v2\/pages\/47\/revisions"}],"predecessor-version":[{"id":1539,"href":"https:\/\/crmw.fr\/index.php?rest_route=\/wp\/v2\/pages\/47\/revisions\/1539"}],"up":[{"embeddable":true,"href":"https:\/\/crmw.fr\/index.php?rest_route=\/wp\/v2\/pages\/89"}],"wp:attachment":[{"href":"https:\/\/crmw.fr\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=47"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}